Chugai Launches Phesgo Subcutaneous Combination for the Treatment of HER2-Positive Breast and Colorectal Cancer
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that it launched Phesgo® combination for Subcutaneous Injection MA, IN [generic name: pertuzumab (genetical recombination), trastuzumab (genetical recombination) and vorhyaluronidase alfa (genetical recombination) ] (hereafter,…
Bayer invests 130 million EUR in new production facility for innovative parenteral products
Bayer has added a brand new manufacturing facility to its global supply chain network. The new production plant was inaugurated today at the company’s global pharmaceutical headquarters in Berlin, Germany.…
Bayer Championing Advancements in Radiology Pipeline and Accelerating AI Innovation
Bayer continues to advance its comprehensive Radiology portfolio with progress in the development pipeline of its investigational contrast agent as well as new innovations in the area of Artificial Intelligence…
Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO® in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency (EMA) has validated a Type II variation application to the Marketing Authorization for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor. The application is for…
European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of children with cystic…
AMGEN TO PRESENT AT THE EVERCORE ISI HEALTHCONX CONFERENCE
Amgen (NASDAQ:AMGN) will present at the Evercore ISI HealthCONx Conference at 9:10 a.m. EST on Wednesday, Nov. 29, 2023. Peter H. Griffith, executive vice president and chief financial officer at Amgen, and Paul Burton, senior vice president and chief…
Novo Nordisk invests more than 16 billion Danish kroner in expansion of production facilities in Chartres, France
Novo Nordisk today announced the investment of more than 16 billion Danish kroner (2.1 billion euros) starting in 20231 to expand the existing production site in Chartres, France, for the current…
Marinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD Study
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the acceptance of seven abstracts for presentation at the upcoming…
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the closing of its previously announced public offering of 2,490,000 shares of its common…
MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced strong topline results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib…
Colibri Group Announces Strategic Acquisition of TRC Healthcare
Colibri Group (“Colibri”), a professional education company with leading brands that provide learning solutions to licensed professionals, announces today that the company has acquired TRC Healthcare. With the addition of…
Prospection AI Launches as the Single-source Patient-centric Intelligence Platform to Strengthen Drug Commercialization
Prospection—the pioneer of patient-centric intelligence—today announced the availability of Prospection AI, its self-service patient-centric intelligence (PCI) platform designed to save life sciences commercial organizations time and money by unlocking insights into…